Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant reduction in the risk of disease progression or death in patients with previously ...

Panel participants share an optimistic outlook for integrating new innovations, tacking community-level challenges, and more.

The past few years have been a roller coaster ride for M&A in pharma and biotech. After the highs of the pandemic came ...

Ash Shehata from KPMG discusses how investors are feeling about the pharma and life sciences industry heading into 2025.

A new offering in collaboration with Progyny, Inc makes fertility/family-building services more accessible and equitable.

Pharmaceutical companies’ direct-to-patient (DTP) programs have recently sparked conversations and criticism in fear of their potential to “cut out” or influence physicians, the truth is that ...

Casey McPherson, Founder and CEO of Chrysalis Genetics, talks about his daughter's rare genetic condition, and how it led him to antisense oligonucleotides (ASOs) and therapeutic development for rare ...

As part of the Inflation Reduction Act, price negotiations with manufacturers will begin this year, with reduced prices expected to take effect in 2027. The Department of Health and Human Services ...

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk of disease progression or death by 27% in patients with previously ...

Organizations including Gilead, Eli Lilly, and AbbVie announced a number of deals addressing inflammatory diseases, multiple myeloma, and other disease areas. With the start of the annual JP Morgan ...

The digital transformation of the pharmaceutical industry continues to provide innovative ways to improve the clinical research process. With the growing importance of strategies like real-time data ...